{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}],"title":"Complete Response (CR)"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}],"title":"Partial Response (PR)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Progression of Disease (POD)"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Stable Disease (SD)"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}],"title":"Very Good Partial Response (VGPR)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"\\[Complete Response (CR) (Normalization of the free light chain (FLC)levels and ratio; Negative serum and urine ; \\<5% plasma cells in bone marrow), Very Good Partial Response (VGPR) (Reduction in the dFLC (difference between involved \\[iFLC\\] and uninvolved FLC) to\\<4mg/dl) and Partial Response (PR)\\] (\\>/= 50% reduction in the dFLC), achieved at 12 month, and at 24 months post-initiation of treatment following the 3-phase comprehensive treatment approach.","groups":[{"description":"Participants with newly diagnosed AL amyloidosis","id":"OG000","title":"Amyloidosis"},{"description":"Participants with newly diagnosed Monoclonal Ig DepositionDisease (MIDD)","id":"OG001","title":"Monoclonal Ig DepositionDisease (MIDD)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"To Estimate the Hematologic Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}